Quick Facts

Chemical Name
Modified Growth Hormone Releasing Hormone
Also Known As
CJC-1295 DAC, CJC-1295 without DAC
Category
Growth Hormone
Administration
Administered via subcutaneous injection

What is CJC-1295?

CJC-1295 is a 30-amino acid peptide analog of GHRH that has been modified to extend its half-life in the body. It comes in two forms: with Drug Affinity Complex (DAC), which extends its half-life to 6-8 days, and without DAC (also known as Mod GRF 1-29), which has a half-life of about 30 minutes. The peptide works by stimulating the pituitary gland to release growth hormone in a more sustained manner than natural GHRH.

How Does CJC-1295 Work?

CJC-1295 binds to GHRH receptors on the pituitary gland, stimulating the production and release of growth hormone. Unlike direct GH administration, this allows for a more physiological pattern of GH release. The DAC modification allows the peptide to bind to serum albumin, dramatically extending its half-life and creating more sustained GH elevation. The non-DAC version provides GH pulses similar to natural release patterns.

Research-Backed Benefits

Sustained GH Elevation

Strong Evidence

Provides more consistent growth hormone levels compared to short-acting secretagogues.

Improved Body Composition

Moderate Evidence

May support muscle mass development and fat reduction through elevated GH.

Enhanced Recovery

Moderate Evidence

Higher GH levels may improve recovery from exercise and physical stress.

Better Sleep Quality

Moderate Evidence

May enhance sleep depth and quality through GH modulation.

Skin and Tissue Health

Emerging Research

GH elevation may improve skin elasticity and overall tissue health.

Dosage Guidelines

Disclaimer: This content is for educational purposes only. Peptides are research compounds not approved by the FDA for human use. Always consult with a qualified healthcare provider.

Typical Range
DAC: 1-2 mg weekly; No DAC: 100-300 mcg per dose
Frequency
DAC: 1-2x weekly; No DAC: 2-3x daily
Duration
8-16 weeks

Often combined with GHRP peptides like Ipamorelin for synergistic effects.

Side Effects & Safety

  • Flushing or warmth after injection
  • Water retention
  • Tingling or numbness
  • Increased hunger

Frequently Asked Questions

CJC-1295 DAC has an extended half-life of 6-8 days due to the Drug Affinity Complex, while the no-DAC version has a half-life of about 30 minutes, providing more pulsatile GH release.
Yes, combining CJC-1295 with a GHRP like Ipamorelin creates a synergistic effect, potentially increasing GH release beyond what either peptide achieves alone.
CJC-1295 no-DAC is often taken before bed and/or upon waking on an empty stomach. CJC-1295 DAC can be taken weekly at any time.
Effects on sleep and recovery may be noticed within 1-2 weeks. Body composition changes typically require 8-12 weeks of consistent use.

References

  1. Teichman SL, et al. "Prolonged stimulation of growth hormone release by CJC-1295." Journal of Clinical Endocrinology & Metabolism, 2006. PMID: 16595485

Get the Complete CJC-1295 Research Protocol

Join 50,000+ researchers with instant access to our comprehensive peptide resource.

Continue Your Research